Prospective Analysis of Restorelle in the Treatment of Uterine Prolapse
The purpose of this study is to determine the long term performance of Restorelle system for the treatment of uterine prolapse.
|Condition or Disease||Intervention/Treatment||Phase|
This study is being done to evaluate the performance of the Restorelle system, which uses Smartmesh - an ultra-lightweight mesh for uterine prolapse management. Most patients undergo a hysterectomy i.e. removal of the uterus when they have a prolapse. However, this has often been found to be an unnecessary operation. The investigators are studying the use of the Restorelle mesh system to preserve the uterus when there is a uterine prolapse.
Arms and Interventions
|Other: Restorelle Smartmesh
Surgical procedure for treatment of uterine prolapse will use the device, Restorelle Smartmesh.
Device: Restorelle Smartmesh
Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
Primary Outcome Measures
- Number of patients who present with recurrence of uterine prolapse following surgery as assessed by failing to meet success criteria [Within first two years after surgical procedure]
Success criteria will be defined through the examination of patient's Prolapse Quantification System Assessment (POPQ) score of C -1 or less and patient's report of bothersome bulge they can see or feel per Pelvic Floor Distress Inventory Short Form 20 (PFDI-20) question 3, response of 0 or 1 (i.e. response of "not at all"). Failure to meet this criteria will be considered recurrence of uterine prolapse.
Subject is female.
Subject is at least 18 years of age.
Subjects who have already made the decision to proceed with uterine prolapse surgery using Restorelle Mesh.
Subject has uterine prolapse defined by Prolapse Quantification System Assessment (POPQ) score of C -2 or greater.
Subject reports a bothersome bulge they can see or feel per Pelvic Floor Distress Inventory Short Form 20 (PFDI-20) question 3, response of 2 or higher (i.e. response of "somewhat", "moderately" or "quite a bit").
Subject is willing to provide written informed consent.
Subject is willing and able to comply with follow-up regimen.
Subject is pregnant or intends to become pregnant in the future.
Subject has a history of pelvic organ cancer (e.g. uterine, ovarian, bladder or cervical).
Subject has undergone any previous repair for pelvic organ prolapse.
Subject has undergone a hysterectomy.
Subject lacks competency of the English language.
Contacts and Locations
|1||Advanced Urogynecology of Michigan, P.C.||Dearborn||Michigan||United States||48125|
Sponsors and Collaborators
- Michigan Institution of Women's Health PC
- Coloplast A/S
- Principal Investigator: Salil Khandwala, Advanced Urogynecology of Michigan, P.C.
Study Documents (Full-Text)None provided.
- IISP 16-05